دورية أكاديمية
People living with HIV co-infected with the Kaposi Sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
| العنوان: | People living with HIV co-infected with the Kaposi Sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma. |
|---|---|
| المؤلفون: | Suterio DG; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Hunter JR; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Tenore SB; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.; Assistência, Centro de Referência e Treinamento em DST/AIDS, São Paulo, São Paulo, SP, Brazil., Pimentel SR; Assistência, Centro de Referência e Treinamento em DST/AIDS, São Paulo, São Paulo, SP, Brazil., Galinskas J; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Dias DA; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Bellini DC; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Ferreira PA; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil., Diaz RS; Retrovirology Laboratory, Infectious Diseases Division, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil. |
| المصدر: | Journal of medical virology [J Med Virol] 2024 Aug; Vol. 96 (8), pp. e29840. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Sarcoma, Kaposi*/virology , HIV Infections*/complications , HIV Infections*/drug therapy , HIV Infections*/virology , Herpesvirus 8, Human*/genetics , tat Gene Products, Human Immunodeficiency Virus*/genetics , Coinfection*/virology , Coinfection*/drug therapy, Humans ; Male ; Female ; Adult ; Middle Aged ; HIV-1/genetics ; HIV-1/drug effects ; Genetic Variation ; Viral Load ; Anti-Retroviral Agents/therapeutic use ; CD4 Lymphocyte Count |
| مستخلص: | Kaposi sarcoma (KS) is a neoplasm of vascular origin that promotes angiogenesis and the growth of endothelial cells triggered by the Kaposi Sarcoma-associated Herpes Virus (KSHV). When associated with HIV, KSHV becomes more aggressive and rapidly evolves. The HIV-1 TAT protein can be essential in developing AIDS-associated KS by promoting angiogenesis and increasing KSHV replication. Therefore, we evaluated the genetic profile of the first exon of tat gene among groups of people living with HIV (PLHIV) with (case group, n = 36) or without KS, this later with (positive control group, n = 46) and without KSHV infection (negative control group, n = 24); all individuals under antiretroviral therapy. The genetic diversity, the DN/DS ratio, and the genetic entropy of the first exon of tat were higher in the case group, followed by the positive control group, which was higher than the negative control group. The number of tat codons under positive selection was seven in the case group, six in the positive control group, and one in the negative control group. The prevalence of HIV viral loads below the detection limit was equal in the case and positive control groups, which were lower than in the negative control group. The mean CD4+ T cell counts were higher in the negative control group, followed by the positive control group, and followed by the case group. These results emphasize the negative influence of KSHV in antiretroviral treatment, as well as the HIV-specific TAT profile among PLHIV who developed KS. (© 2024 Wiley Periodicals LLC.) |
| References: | Braun M. Moriz Kaposi, M.D. CA Cancer J Clin. 1982;32(6):340‐341. doi:10.3322/canjclin.32.6.340. Sternbach G, Varon J. Moritz Kaposi: idiopathic pigmented sarcoma of the skin. J Emerg Med. 1995;13(5):671‐674. doi:10.1016/0736-4679(95)00077-n. Jr WH, Sieczkowski L, Sosa C, et al. Activation of HHV‐8 by HIV‐1 tat. Lancet. 1997;349(9054):774‐775. doi:10.1016/s0140-6736(05)60199-7. Caselli E, Galvan M, Cassai E, Di Luca D. Transient expression of human herpesvirus‐8 (Kaposi's sarcoma‐associated herpesvirus) ORF50 enhances HIV‐1 replication. Intervirology. 2003;46(3):141‐149. doi:10.1159/000071454. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong‐Staal F. Tat protein of HIV‐1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 1990;345(6270):84‐86. doi:10.1038/345084a0. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature. 1988;335(6191):606‐611. doi:10.1038/335606a0. Johri MK, Mishra R, Chhatbar C, Unni SK, Singh SK. Tits and bits of HIV Tat protein. Expert Opin Biol Ther. 2011;11(3):269‐283. doi:10.1517/14712598.2011.546339. Diaz RS, Oliveira CFD, Pardini R, Operskalski E, Mayer AJ, Busch MP. HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1‐infected individuals. AIDS Res Hum Retroviruses. 1999;15(13):1151‐1156. doi:10.1089/088922299310241. Batista MD, Ferreira S, Sauer MM, et al. High human herpesvirus 8 (HHV‐8) prevalence, clinical correlates and high incidence among recently HIV‐1‐infected subjects in Sao Paulo, Brazil. PLoS One. 2009;4(5):e5613. doi:10.1371/journal.pone.0005613. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position‐specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673‐4680. doi:10.1093/nar/22.22.4673. Trifinopoulos J, Nguyen LT, vonHaeseler A, Minh BQ. W‐IQ‐TREE: a fast online phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. 2016;44(W1):W232‐W235. doi:10.1093/nar/gkw256. Siepel AC, Halpern AL, Macken C, Korber BTM. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995;11(11):1413‐1416. doi:10.1089/aid.1995.11.1413. Zhang M, Schultz AK, Calef C, et al. jpHMM at GOBICS: a web server to detect genomic recombinations in HIV‐1. Nucleic Acids Res. 2006;34(Web Server issue):W463‐W465. doi:10.1093/nar/gkl255. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol. 1986;3(5):418‐426. doi:10.1093/oxfordjournals.molbev.a040410. Ota T, Nei M. Variance and covariances of the numbers of synonymous and nonsynonymous substitutions per site. Mol Biol Evol. 1994;11(4):613‐619. doi:10.1093/oxfordjournals.molbev.a040140. Murrell B, Wertheim JO, Moola S, Weighill T, Scheffler K, Kosakovsky Pond SL. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 2012;8(7):e1002764. doi:10.1371/journal.pgen.1002764. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731‐2739. doi:10.1093/molbev/msr121. Renwick N, Halaby T, Weverling GJ, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS. 1998;12(18):2481‐2488. doi:10.1097/00002030-199818000-00018. Zeng Y, Zhang X, Huang Z, et al. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma‐associated herpesvirus: role of JAK/STAT signaling. J Virol. 2007;81(5):2401‐2417. doi:10.1128/JVI.02024-06. Mitola S, Soldi R, Zanon I, et al. Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells. J Virol. 2000;74(1):344‐353. doi:10.1128/jvi.74.1.344-353.2000. Rusnati M, Presta M. HIV‐1 Tat protein and endothelium: from protein/cell interaction to AIDS‐associated pathologies. Angiogenesis. 2002;5(3):141‐151. doi:10.1023/a:1023892223074. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV‐1 Tat: a polypeptide for all seasons. Immunol Today. 1998;19(12):543‐545. doi:10.1016/s0167-5699(98)01351-6. Lopes AO, Marinho PN, Medeiros LAS, de Paula VS. Human gammaherpesvirus 8 oncogenes associated with Kaposi's sarcoma. Int J Mol Sci. 2022;23(13):7203. doi:10.3390/ijms23137203. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707‐719. doi:10.1038/nrc2888. Bhutani M, Polizzotto MN, Uldrick TS, Yarchoan R. Kaposi sarcoma‐associated herpesvirus‐associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol. 2015;42(2):223‐246. doi:10.1053/j.seminoncol.2014.12.027. Cantaluppi V, Biancone L, Boccellino M, et al. HIV type 1 Tat protein is a survival factor for Kaposi's sarcoma and endothelial cells. AIDS Res Hum Retroviruses. 2001;17(10):965‐976. doi:10.1089/088922201750290087. Ensoli B, Stürzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev. 1998;9(1):63‐83. doi:10.1016/s1359-6101(97)00037-3. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Biberfeld P. KSHV/HHV‐8 and HIV infection in Kaposi's sarcoma development. Infect Agent Cancer. 2007;2:4. doi:10.1186/1750-9378-2-4. Aoki Y, Tosato G. HIV‐1 Tat enhances Kaposi sarcoma‐associated herpesvirus (KSHV) infectivity. Blood. 2004;104(3):810‐814. doi:10.1182/blood-2003-07-2533. Diaz RS, Zhang L, Busch MP, Mosley JW, Mayer A. Divergence of HIV‐1 quasispecies in an epidemiologic cluster. AIDS. 1997;11(4):415‐422. doi:10.1097/00002030-199704000-00003. de Carvalho Lima EN, Lima RSA, Arif MS, Piqueira JRC, Diaz RS. Evolutive temporal footprint of an HIV‐1 envelope protein in an epidemiologically linked cluster. Open AIDS J. 2020;14(1):41‐49. doi:10.2174/1874613602014010041. de Carvalho Lima EN, Lima RSA, Piqueira JRC, et al. Evidence of genomic information and structural restrictions of HIV‐1 PR and RT gene regions from individuals experiencing antiretroviral virologic failure. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;78:104134. doi:10.1016/j.meegid.2019.104134. Lima ENC, Piqueira JRC, Camargo M, Galinskas J, Sucupira MC, Diaz RS. Impact of antiretroviral resistance and virological failure on HIV‐1 informational entropy. J Antimicrob Chemother. 2018;73(4):1054‐1059. doi:10.1093/jac/dkx508. |
| معلومات مُعتمدة: | Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo |
| فهرسة مساهمة: | Keywords: HIV‐1; Kaposi Sarcoma‐associated Herpes Virus; Kaposi sarcoma; tat |
| المشرفين على المادة: | 0 (tat Gene Products, Human Immunodeficiency Virus) 0 (Anti-Retroviral Agents) |
| تواريخ الأحداث: | Date Created: 20240802 Date Completed: 20240802 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| DOI: | 10.1002/jmv.29840 |
| PMID: | 39092805 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.29840 |